Why Vanda Pharmaceuticals (VNDA) Stock Fell 10.69% in 10 Minutes on Oct 14, 2026
The 10.69% drop was larger than any reaction MoveSurge measured after Vanda Pharmaceuticals headlines between Jul 16, 2026 and Oct 13, 2026; the largest of those was +4.50% in 15 minutes, on Aug 24, 2026.
- VNDA fell 10.69% in the 10 minutes after the 17:00:13 ET headline, from $4.21 to $3.76.
- 54,270 shares changed hands in those 10 minutes.
- The headline crossed in after-hours trading, 1 hour after the 4:00 ET close.
17:00:13 ET
Reaction by asset (real prices)
| Asset | 2m before | At release | +1m | +10m | +1m % | +10m % |
|---|---|---|---|---|---|---|
| VNDA | 4.21 | 4.21 | 3.50 | 3.76 | -16.87% | -10.69% |
Vanda Pharmaceuticals (VNDA) shares fell 10.69% in the 10 minutes after this headline reached the MoveSurge news feed at 17:00:13 ET on Wednesday, October 14, 2026: “Vanda Pharmaceuticals says Phase III study missed a key secondary endpoint in the full population”
VNDA in the first 10 minutes
From a reference price of $4.21 just before the headline, the stock was down 16.87% after one minute and down 10.69%, at $3.76, after 10 minutes. Part of the first-minute move came back by the 10-minute mark. 54,270 shares changed hands in those 10 minutes. The headline crossed in after-hours trading, 1 hour after the 4:00 ET close.
Earlier VNDA headlines and the measured reaction
The 10.69% drop was larger than any reaction MoveSurge measured after Vanda Pharmaceuticals headlines between Jul 16, 2026 and Oct 13, 2026; the largest of those was +4.50% in 15 minutes, on Aug 24, 2026.
- Aug 24, 2026, 07:04 ET: “Vanda Pharmaceuticals Receives EMA Orphan Designation for Imsidolimab to Treat Generalized Pustular Psoriasis” (+4.50% in 15 minutes)
Vanda Pharmaceuticals at a glance
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Market value | $275 million (as of Oct 14, 2026) |
| Next earnings report on the calendar | Wednesday, November 4, 2026 |
Prices are closes of 1-minute bars. Each move on this page is measured from the last completed bar before its headline.
What headline moved Vanda Pharmaceuticals stock on October 14, 2026?
At 17:00:13 ET, this headline crossed: “Vanda Pharmaceuticals says Phase III study missed a key secondary endpoint in the full population”. The stock fell 10.69% in the next 10 minutes.
How far did VNDA move after the headline?
From $4.21 just before the headline to $3.76 10 minutes later, a -10.69% move.
When does Vanda Pharmaceuticals report earnings next?
The next report on the MoveSurge earnings calendar is Wednesday, November 4, 2026.
Sources
-
VNDA headline and measured reaction, Oct 14, 2026
— MoveSurge
The headline as it crossed, its timestamp, and the measured price reaction reported on this page.
Never miss the next market-moving story
Follow the core market-moving feed across equities, macro, currencies and commodities. Your subscription includes recorded price reactions, search, watchlists, alerts and research tools.
Create free accountGo real time Watch live headlines -- free